(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate(CAS: 33069-62-4)
![(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate](https://cnstatic.chemtradehub.com/structs/330/33069-62-4-4aa0.webp)
CAS号
相关产品
Mogroside V
CAS号: 88901-36-4
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
CAS号: 760961-03-3
Withaferin A
CAS号: 5119-48-2
其他供应商提供的 (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
基本信息
分子式
C47H51NO14
分子量
853.92 g/mol
物理状态
Powder
Physical Properties
熔点
213-216 ºC
沸点
957.1°C at 760 mmHg
闪点
9℃
化学标识符
SMILES
CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(=O)C)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7
InChIKey
RCINICONZNJXQF-MZXODVADSA-N
数据库引用
MDL号
MFCD00869953
Beilstein登记号
1420457
常见问题
紫杉醇是一种从红豆杉树皮和木材中提取的天然抗癌药物,CAS号为33069-62-4。其化学结构包含一个复杂的多环体系,由两个六元环通过桥头连接形成,侧链上带有乙酰氧基、羟基和苯甲酸酯基团。该化合物通过抑制微管解聚,稳定细胞分裂过程,从而发挥抗肿瘤作用,是治疗多种癌症的重要药物。
紫杉醇主要用于治疗乳腺癌、卵巢癌、肺癌、淋巴瘤等恶性肿瘤。作为细胞周期抑制剂,它通过干扰癌细胞的微管功能,阻止细胞分裂,诱导程序性死亡。此外,其衍生物如多西他赛也被广泛应用于临床,常与其他化疗药物联合使用以提高疗效。
紫杉醇作为处方药需在医生指导下使用,其安全性与剂量和个体差异相关。常见不良反应包括骨髓抑制、神经毒性、过敏反应及低血压,使用时需监测血常规和肝肾功能。操作人员应佩戴防护手套、口罩等避免接触,孕妇及哺乳期妇女禁用。需严格遵循医疗规范以减少风险。
紫杉醇应储存于阴凉、干燥、避光的环境中,温度控制在2-8℃,避免高温和潮湿。需密封保存于棕色玻璃瓶或金属容器中,防止光照降解。储存时远离强酸、强碱等腐蚀性物质,确保通风良好。运输和保管过程中需避免剧烈震动,保持包装完整。
安全须知
使用前请验证产品规格和安全数据。联系供应商获取详细安全信息。
请始终遵循正确的操作程序
联系信息
邮箱
1569593439@qq.com

![(1S,2R,4R,5R,6S,8R,10S,11S,12R,14R,15R,16R,19S,21R)-6-(3-Furyl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0~1,14~.0~2,11~.0~5,10~.0~8,10~]henicosane-4,21-diyl diacetate](https://cnstatic.chemtradehub.com/structs/588/58812-37-6-c4a7.webp)


![[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate](https://cnstatic.chemtradehub.com/structs/760/760961-03-3-e1aa.webp)



![(4S,5R,6R,14R)-4,5,6-Trihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0~1,5~.0~10,12~]pentadeca-2,7-dien-12-yl laurate](https://cnstatic.chemtradehub.com/structs/547/54706-70-6-5473.webp)

![(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate — 南京普怡生物科技有限公司](https://cnstatic.chemtradehub.com/suppliers/67cecda42b2de6e8e95a5fa6/67cecda42b2de6e8e95a5fa6-logo.webp)
![(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate — 湖北扬信医药科技有限公司](https://cnstatic.chemtradehub.com/suppliers/67cded3957537e5c8069af88/67cded3957537e5c8069af88-logo.webp)